Results 231 to 240 of about 929,362 (315)

Improvement of Microangiopathy in A Systemic Sclerosis Patient Following Hysterectomy for Leiomyoma: A Potential Role of Neoplasia. [PDF]

Eur J Case Rep Intern Med
Nigro A, Santarcangelo P, Bonelli A, Digregorio S, Mazzoccoli C, Nicoletti G.   +5 more
europepmc   +1 more source

Systemic Sclerosis Presenting as Arrythmogenic Cardiomyopathy: A Case Series. [PDF]

CJC Open
Diallo EH, Cadrin-Tourigny J, Hoa S, Laghzali NB, Potter BJ, Landon-Cardinal O, Raymond JM.   +6 more
europepmc   +1 more source

Treating comorbidities in MS is disease modifying: Commentary. [PDF]

Mult Scler
Palladino R.
europepmc   +1 more source

Hand functional capacity in women with systemic sclerosis using the Glittre-ADL-Shelf test: Relationship with demographics, body composition, hand function, physical function, digital dexterity, muscle strength and lung function. [PDF]

J Scleroderma Relat Disord
Duarte FSP, da Nobrega Ferreira I, Beserra ADS, Barbosa NO, da Silva LL, de Souza VCV, Gomes V, Lopes AJ.   +7 more
europepmc   +1 more source

Ophthalmic Posterior Segment OCTA Metrics as Potential Biomarkers for Systemic Involvement in Systemic Sclerosis, Systemic Lupus Erythematosus, and Behçet Disease: A Systematic Review. [PDF]

Open Access Rheumatol
Drakopoulos M, Sikora HF, Fahey JD, Mirza RG.   +3 more
europepmc   +1 more source

Full Recovery Over One Year of the Overlap Syndrome Scleromyositis to Maintenance Therapy with Mycophenolate Mofetil and Rituximab, which Relapsed within 8 Months of Discontinuation. [PDF]

Eur J Case Rep Intern Med
Amarante I, Faustino C, Mota B, Cascais M, Almeida J, Valentim M.   +5 more
europepmc   +1 more source

Arrhythmia as a Possible Complication of Mycophenolate Mofetil in Systemic Sclerosis: A Case Report. [PDF]

Case Rep Med
Moradi Z, Ardestani V, Tamartash Z, Karimi E, Kavosi H.   +4 more
europepmc   +1 more source

Interstitial lung disease in anti-U1RNP systemic sclerosis patients: A European Scleroderma Trials and Research analysis. [PDF]

J Scleroderma Relat Disord
Boleto G, Campochiaro C, Distler O, Balanescu A, Launay D, Bergmann C, Airò P, Oksel F, Gheorghiu AM, Anic B, Mouthon L, Yavuz S, Tanaseanu CM, Matucci-Cerinic M, Allanore Y.   +14 more
europepmc   +1 more source

Evaluation of Systemic Sclerosis Primary Heart Involvement and Chronic Heart Failure in the European Scleroderma Trials and Research Cohort. [PDF]

J Am Heart Assoc
Györfi AH, Filla T, Polzin A, Tascilar K, Buch M, Tröbs M, Matei AE, Airo P, Balbir-Gurman A, Kuwert F, Mihai C, Kabala A, Graßhoff H, Callaghan J, Isomura Y, Mansour J, Spierings J, Tennoe AH, Selvi E, Riccieri V, Hoffmann-Vold AM, Bergmann C, Schett G, Hunzelmann N, van Laar JM, Saketkoo LA, Kuwana M, Siegert E, Riemekasten G, Distler O, du Four T, Smith V, Truchetet ME, Distler JHW, EUSTAR collaborators.   +34 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Progressive Systemic Sclerosis Sine Scleroderma

JAMA, 1962
Four patients, a man aged 51 and 3 women aged 59, 69, and 71, died of progressive systemic sclerosis and yet had minimal or no evidence of cutaneous disease (scleroderma). In addition to illustrating the great variability in the clinical course of progressive systemic sclerosis, these cases serve to point up the difficulties involved in the recognition
Gerald P. Rodnan, Robert H. Fennell
openaire   +4 more sources